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DLEC1 (deleted in lung and esophageal cancer 1) is located at 3p22-p21.3 and 
encodes for a 1755-amino acid polypeptide (Rauch et al., 2006; Daigo et al., 1999). It 
is a novel candidate tumor suppressor gene that markedly suppressed colony 
formation in cancer cell lines and reduced tumorigenesis in nude mice (Daigo et al., 
1999; Kwong et al., 2006; Qiu et al., 2008). It was frequently down-regulated by 
promoter hypermethylation and histone hypoacetylation in cancer cell lines (Kwong 
et al., 2006; Qiu et al., 2008; Seng et al., 2008). The exact biologic function is still 
unclear and the predicted amino acid sequence of DLEC1 has no significant 
homology to any of the known proteins or peptides (Daigo et al., 1999). This study 
was aimed to provide some knowledge regarding the regulation and function of 
DLEC1 in colorectal cancer. 
In HCT116 cell line, the PI3K-AKT-mTOR, JNK-SAPK, Ras-Raf-MEK-ERK 
pathways are constitutively activated. To study the possible mechanism of regulation 
of DLEC1 by these signaling pathways, RT-PCR was performed to screen for 
potential drugs that could alter DLEC1 expression. U0126, a specific MEK inhibitor, 
was shown to be able to up-regulate DLEC1 in a dose-dependent manner. Transient 
over-expression of DLEC1 as well as treatment using U0126 both suppressed cell 
proliferation in HCT116 cells. The growth suppressing effect of DLEC1 was 
confirmed by anchorage dependant colony formation assay. Stable clones of HCT116 
expressing DLEC1 showed increased G1 cycle arrest, implying that the inhibitory 
effect of DLEC1 on cell growth and survival may be caused by G1 arrest. To study 
the possible mechanism involved, we screened for the expression levels of potential 





been up-regulated in DLEC1 over-expressing stable cell lines. Together, our data 
suggested that DLEC1 is suppressed by Ras-Raf-MEK-ERK pathway in HCT116 cell 
line; it has growth inhibitory effect on HCT116 cells, and the possible mechanism 
involved may be G1 cell cycle arrest, which was contributed by the up-regulation of 



























Cancer is an increasingly prevalent health-care problem worldwide. It has been 
estimated that over 12 million people have been diagnosed with cancer last year, 
according to the World Cancer Report 2008 by the World Health Organization (World 
Cancer Report, 2003).   
Cancer is a class of diseases or disorders characterized by uncontrolled cell 
growth and the ability of these cells to spread, either through invasion or metastasis. 
The development of cancer is a multi-step process influenced by both environmental 
and endogenous factors. Genetic abnormalities found in cancer typically affect two 
general classes of genes: oncogenes and tumor suppressor genes (TSG). Alteration of 
these genes are responsible for self-sufficiency in growth signals , insensitivity to 
negative growth signaling, tissue invasion and metastasis, induction of angiogenesis 
and evasion from apoptosis, which are known as hallmarks of cancer (Hanahan and 
Weinberg, 2000). Despite major advances in cancer research over the years, diagnosis, 
prognosis and cancer treatment are still unsatisfactory.   
 
2.2 Colorectal carcinoma 
Colorectal cancer, also called colon cancer or bowel cancer, includes cancerous 
growths in the colon, rectum and appendix. It is the third most common form of 
cancer and the second leading cause of death among cancers in the western world 





colorectal cancer is the most common cancer, with nearly 1000 cases diagnosed 
annually (National Cancer Centre Singapore).  
 
2.2.1 Etiologies of colorectal carcinoma 
The causes of colorectal cancer are not yet fully understood. The most important 
factors include the interaction of cell molecular changes and environmental factors, 
with a great emphasis on diet components. Several risk factors are commonly found in 
diets, such as high concentrations of fat and animal protein, as well as low amounts of 
fiber, fruits and vegetables. Excess body weight and excess energy intake have also 
been associated to colorectal carcinoma, as well as personal habits such as physical 
inactivity, high alcohol consumption and smoking (Campos et. al., 2005). 
 
2.2.2 Genetics of colorectal carcinoma 
Colorectal cancer is a disease originating from the epithelial cells lining the 
gastrointestinal tract. The transition from normal epithelium to carcinoma is 
associated with acquired molecular events (Fearon and Vogelstein, 1990). There are 
at least two major pathways by which these molecular events can lead to colorectal 
cancer. About 85% of colorectal cancers are due to events that result in chromosomal 
instability (CIN) and the other 15% are due to events that result in microsatellite 
instability (MSI or MIN) (Kinzler and Vogelstein, 1998; Lengauer et al., 1998; 
Lindblom, 2001). 
Key changes in CIN cancers include widespread alterations in chromosome 





18q, and 17p. Various causes for these mutations are inborn genetic aberrations, 
environmental, and possibly viral causes. Chromosome losses are associated with 
instability at the molecular and chromosomal level (Lengauer et al., 1998).  
The key characteristics of MSI cancers are that they are tumors with a largely 
intact chromosome, and as a result of defects in the DNA mismatch repair system, 
they acquire mutations in important cancer-associated genes more readily than cells 
that have an effective DNA mismatch repair system. These types of cancers are 
detectable at the molecular level by alterations in repeating units of DNA that occur 
normally throughout the genome, known as DNA microsatellites.  
 
2.3 Tumor Suppressor Genes (TSGs) 
Tumor suppressor genes are negative regulators of growth or any processes 
related to tumor’s invasion and metastasis. They can be divided into two categories 
based on their gene function: gatekeepers and caretakers (Kinzler and Vogelstein, 
1997). Gatekeepers prevent carcinogenesis directly by controlling the balance 
between cell proliferation and cell death. Inactivation of gatekeepers is the rate 
limiting step for the development of tumor. In contrast, caretaker genes prevent 
malignant transformation indirectly by maintaining genomic integrity.  
TSGs either have a repressive effect on the regulation of the cell cycle or 
promote apoptosis, and sometimes do both. The functions of tumor suppressor genes 
fall into several categories including the following: repression of genes that are 
essential for the continuing of the cell cycle; coupling the cell cycle to DNA damage 





to prevent tumor cells from dispersing, and inhibit metastasis (Hirohashi and Kanai, 
2003). 
Due to the importance of TSGs, much effort has been put into identification of 
candidate TSGs in various types of tumors. 
 
2.3.1 Identified TSGs in Colorectal Carcinoma 
One major challenge in the colorectal carcinoma research is the identification 
and characterization of tumor suppressors whose inactivation or down-regulation 
alters major cellular signaling pathways. 
Colorectal cancer has been found to be associated with the deletion of multiple 
chromosomal regions including chromosomes 5q, 17p, and 18q. Such chromosome 
loss is often suggestive of the deletion or loss of function of TSGs. The candidate 
tumor suppressor genes from these chromosomal regions are, respectively, the 
Mutated in Colorectal Cancer (MCC), Adenomatous Polyposis Coli (APC), p53, and 
the Deleted in Colorectal Cancer (DCC). It has been found that while multiple defects 
in tumor suppressor genes seem to be required for progression to the malignant state 
in colorectal cancer, correction of only a single defect can have significant effects in 
vivo and/or in vitro (Goyette et al., 1992).  
 
2.3.1.1 DLEC1 as a candidate tumor suppressor gene in colorectal carcinoma 
DLEC1 (deleted in lung and esophageal cancer 1) was first identified in 1999 by 
Daigo et al (known as DLC1 – deleted in lung cancer 1). It is located at the AP20 sub-





aberrations and loss of heterozygosity in cancers. (Qiu et al., 2008). It encodes for a 
1755-amino acid polypeptide, which has no significant homology to any of the known 
proteins or domains (Daigo et al., 1999).  
It has been hypothesized that DLEC1 was a candidate tumor suppressor gene in 
hepatocellular carcinoma (Qiu et al., 2008), lung cancer (Seng et al., 2008), ovarian 
cancer (Kwong et al., 2006), as well as colon and gastric cancers (Ying et al., 2009). 
DLEC1 is robustly expressed in normal tissues but silenced in tumor cell lines (Qiu et 
al., 2008). Studies have shown that over-expression of DLEC1 markedly suppressed 
colony formation in some cancer cell lines (Daigo et al., 1999; Kwong et al., 2006) 
and reduced tumorigenesis in nude mice (Kwong et al., 2007). Furthermore, stable 
cell lines which expressed DLEC1 also showed reduced invasiveness and tumerigenic 
properties (Kwong et al., 2007). Previous studies have also demonstrated that DLEC1 
was frequently down-regulated by promoter hypermethylation and histone 
hypoacetylation (Kwong et al., 2006), and the methylation status is associated with 
AJCC staging of the tumors (Qiu et al., 2008).  
 
2.4 Oncogenes 
An oncogene is a modified gene that codes for a protein which increases the 
malignancy of a tumor cell. A proto-oncogene is a normal gene that can become an 
oncogene, either by mutation or increased expression. Proto-oncogenes code for 
proteins that help to regulate cell growth and differentiation. Proto-oncogenes are 





Oncogenes are commonly divided into several categories: growth factors, 
tyrosine kinases, serine/threonine kinases, regulatory GTPases and transcription 
factors. 
 
2.5 Epigenetic Gene Regulation 
Epigenetic gene regulation alters the transcriptional activity of genes without 
changing the DNA sequence. Epigenetic control is recognized as the third pathway of 
inactivation of genes besides loss of heterogeneity and gene mutation (Jones and 
Laird, 1999; Baylin and Herman, 2000). Epigenetic gene regulation can be imposed 
by many mechanisms such as DNA methylation, histone modification, local 
nucleosome remodelling, and long-range epigenetic regulations (Lund and van 
Lohuizen, 2004).   
Epigenetic gene regulation collaborates with genetic alterations in cancer 
development. This is evident from every aspect of tumor biology including cell 
growth and differentiation, cell cycle control, DNA repair, angiogenesis, migration, 
and evasion of host immunosurveillance (Lund and van Lohuizen, 2004). 
 
2.5.1 Hypomethylation and hypermethylation 
DNA methylation is the best characterized epigenetic mechanism (Jaenisch et 
al., 2003). It refers to methylation of cytosine at CpG dinucleotides. Most CpG 
dinucleotides are unevenly distributed throughout the genome and remain in short 
stretches or clusters (500–2000 bp), called CpG islands (Feltus et al., 2006). In 





methylation are prevalent in human sporadic cancers (Costello and Plass, 2001). 
Methylation defects include global genome hypomethylation (resulting in 
chromosomal instability and epigenetic activation of oncogenes) and localized 
aberrant hypermethylation of CpG islands, resulting in transcriptional repression of 
many important genes, including tumor suppressor genes (Ting et al. 2006). 
 
2.5.2 Histone Deacetylation 
Histone proteins are subject to a range of post-transcriptional modifications in 
living cells. Acetylation of histone proteins correlates with transcriptional activation 
and a dynamic equilibrium of histone acetylation is governed by the opposing actions 
of histone acetyl transferases (HATs) and histone deacetylases (HDACs). Both HATs 
and HDACs have been found mutated or deregulated in various cancers. 
Histone deacetylases (HDAC) are a class of enzymes that remove acetyl groups 
from a ε-N-acetyl lysine amino acid on a histone. Deacetylation restores the positive 
electric charge of the lysine amino acids, which increases the histone's affinity for the 
negatively charged phosphate backbone of DNA. They are associated with the 
formation of heterochromatin. This generally down-regulates DNA transcription by 
blocking the access of transcription factors. Abnormal HDAC activity has been found 
associated with the development of many types of cancer (Marks et al., 2001; Verdin 
et al., 2003).  
 





Treatment of advanced colorectal cancer increasingly requires a 
multidisciplinary approach, which include surgery, radiation and chemotherapy. The 
drugs that are currently effective against colorectal cancer include 5-fluorouracil (5-
FU), Irinotecan (Camptosar), Capecitabine (Xeloda), Oxaliplarin (Eloxatin), etc. The 
search continues for novel therapeutic strategies and drugs to treat and to overall 
improve the quality of life of CRC patients. Recently novel targeted therapy against 
angiogenesis and epidermal growth factor receptor completed a plethora of phase III 
studies (Chau and Cunningham, 2009), which may bring the cancer patients more 
promising ways of treatments. 
 
2.7 Growth Signaling Pathways as therapeutic targets of colorectal 
cancer 
Inhibitors of the growth signaling pathways have become the therapeutic targets 
of colorectal cancer because studies from recent years provided emerging evidences 
that growth factor receptors and the downstream signaling pathways coupled to them 
play a critical role in the development and progression of colorectal cancer. The 
dysregulation of three signaling pathways have been shown to associate with 
carcinogenesis, namely the PI3K-AKT-mTOR pathway, the JNK-SAPK pathway and 
the Ras-Raf-MEK-ERK pathway (Hopfner et al., 2008). Two of these pathways will 
be focused on in our study. 
 
2.7.1 PI3K-AKT-mTOR pathway 
PI3K-AKT-mTOR pathway is one of the three major signaling pathways that 





generation of phosphatidylinositol 3,4,5-triphosphate (PIP3) which subsequently 
activates AKT, a serine/threonine kinase whose phosphrylation leads to the 
inactivation of pro-apoptotic members while activating anti-apoptotic members 
(Hopfner et al., 2008). Phosphorylation of AKT will also lead to the activation of 
mTOR, which in turn regulates the elements involved in cell proliferation such as 
cyclin D1, c-myc and ornithine decarboxylase, etc (Avila et al., 2006). Under normal 
circumstances, cells contain PTEN phosphatase which negatively regulate PI3K and 
inhibit AKT activation. A reduction in PTEN expression indirectly stimulates PI3K-
AKT-mTOR activity thereby contributing to oncogenesis in human. PI3K-AKT-
mTOR activation affects many tumour types and it is often constitutively activated in 
malignancies such as gastrointestinal cancers, and more particularly in pancreatic, 
gastric and colon cancer. Recent data suggests that the PI3K-AKT-mTOR signaling 
pathway plays an important role in cancer stem cell self-renewal and resistance to 
chemotherapy or radiotherapy, which is believed to be the root of treatment failure 
and cancer recurrence, as well as metastasis. Hence inhibitors that target the key 
elements in this pathway may be of great therapeutic importance. A number of PI3K 
inhibitors are currently under clinical trial in solid tumor cancers.  
 
2.7.2 Ras-Raf-MEK-ERK pathway 
The Ras-Raf-MEK-ERK cascade couples signals from cell surface receptors to 
transcription factors, which regulate expression of the genes that control cell 
proliferation, transformation, differentiation and apoptosis (Kolch, 2000). This 
phosphorylation cascade begins with a membrane bound G-protein Ras, which is 
usually activated by the extracellular growth and differentiation factors; followed by 





Phosphorylation of MEK leads to the activation of ERK1/2, which then triggers the 
downstream gene activation or suppression by either acting on the cytoplasmic 
substrates or translocating into the nucleus (Sridhar et al., 2005). Depending upon the 
stimulus and cell type, this pathway can transmit signals, which result in the 
prevention or induction of apoptosis or cell cycle progression. Abnormal activation of 
this pathway occurs in a number of types of cancers, including HCC, lung cancer, 
colorectal cancer and leukemia. Thus, it is a potential pathway to target for 
therapeutic intervention. To date, inhibitors of Ras, Raf, MEK and some downstream 
targets have been developed and many are currently in clinical trials.  
 
 
2.8 U0126 and MEK inhibitors 
U0126 (IUPAC name 1,4-diamino-2,3-dicyano-1,4-bis (2-
aminophenylthio)butadiene), synthesized in the late 1950's by W. J. Middleton 





inflammatory agent that does not interact with the glucocorticoid response elements 
(GREs), because such interactions are generally responsible for the side effects of 
steroids (Duncia et al., 1998).  
U0126 is a potent inhibitor of MEK (a MAP kinase kinase), a dual specificity 
kinase in the mitogen activated protein kinase (MAPK) cascade (Favata et al., 1998). 
MEK phosphorylates the threonine and tyrosine residues on ERKs 1 and 2 resulting in 
their activation (Zheng and Guan, 1994). Activated ERK, in turn, phosphorylates Elk-
1 leading to transcriptional activation of the cFos and cJUN genes, resulting in AP-1 
activation (Cano and Mahadevan, 1995). Hence, the inhibition of MEK by u0126 
leads to the inactivation of these downstream molecules which are important for cell 
growth.  
MEK plays a key position in the Ras/Raf/MEK/ERK signaling pathway, which 
is frequently activated in human tumors. Inappropriate activation of the MEK/ERK 
pathway promotes cell growth in the absence of exogenous growth factors. As a 
result, a number of MEK inhibitors were developed for the treatment of cancer. For 
example, AZD6244 (ARRY-886), which was licensed to AstraZeneca in 2003, is 
currently in Phase 2 clinical development for the treatment of cancer.  A new oral 
MEK inhibitor, RDEA119, which has showed favorable anti-tumor properties, started 








3 AIMS OF THE PRESENT STUDY 
The DLEC1 gene is aberrantly regulated in many different cancers. This study 
was proposed to investigate the molecular mechanisms that regulated the expression 
of this gene, and the potential functional role of DLEC1 in cellular function and 
proliferation. This will help us better understand how cancers arise and reveal 
possible targets for therapeutic interventions. The specific aims are as follows: 
(1) To identify the possible molecular pathways involved in the regulation of 
DLEC1; 
(2) To study the effect of DLEC1 on cell cycle progression and cell proliferation, and 















4 MATERIALS AND METHODS 
4.1 Cells lines and cell culture 
The HCT116 (human colorectal tumor) and HT29 (colorectal adenocarcinoma) 
cell line was purchased from American Type Culture Collection (Manassas, VA). The 
HCT116 p53 knock out (p53 -/-) cell line was kindly provided by Professor Bert 
Vogelstein from Johns Hopkins University. These cells were cultured in McCoy’s 5A 
medium (Sigma Chemical Co., St. Louis, MO), supplemented with 10% fetal bovine 
serum (GIBCO®, Invitrogen), at 37°C in a 5% CO2 humidified atmosphere. 
 
4.2 Drug treatment 
For treatment with Emodin, SP600125, SB239063, LY294002 and u0126, cells 
were seeded at a density of 0.3×106 cells per well in a 6-well format, cultured 
overnight (24 hrs) and treated for 48 hrs. The concentrations of drugs used were: 
Emodin:  2, 10, 50 and 100µM; SP600125: 10µM; SB239063: 10µM; LY294002: 
30µM; u0126: 2, 5, 10. 25 and 100µM. Dimethyl Sulfoxide (DMSO) was used as a 




The cells were plated in 6-well plates at approximately 0.3×106 cells/well 24hrs 
before tranfections. Transfections were carried out with LipofectamineTM 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol with some 




modifications. In short, 1µg plasmid and 3µl LipofectamineTM 2000 were mixed in 
500µl serum-free Opti-MEM® medium (GIBCO®, Invitrogen) and incubated at room 
temperature for 20min before adding to the cells. Medium was changed 6hrs after the 
transfection. Cells were transfected for 48hrs before assaying.   
 
4.4 DLEC1 Knockdown 
Cells were seeded at 0.3×106 per well in a 6-well plate and cultured for 24 hrs 
before knocking down. Transfection of siRNA was carried out with Lipofectamine 
RNAiMAX Reagent (Invitrogen, Carlsbad, CA) according to the manufacture’s 
protocol with some modifications. In short, 10nM of siRNA (Invitrogen) or scramble 
control (Invitrogen) and 3µl LipofectamineTM RNAiMAX were mixed in 500µl 
serum-free Opti-MEM® medium (GIBCO®, Invitrogen) and incubated at room 
temperature for 20min before adding to the cells. Medium was changed 6hrs after the 
transfection. Cells were transfected for 48hrs before assaying or being harvested for 
further experiments.    
 
4.5 RNA extraction 
Total RNA was extracted using QIAGEN RNeasy Mini Kit (QIAGEN, Hilden, 
Germany) according to manufacturer’s instructions. The quality and concentration of 
the extracted RNA was assessed with a fluorospectrometer (Nanodrop, Wilmingtong, 
DE, USA) according to the manufacturer’s instructions. 260/280 and 260/230nm 
absorbance ratios of 1.8-2.0 indicate a pure RNA sample.   
 




4.6 Reverse transcription 
The cDNA was synthesized by using ImProm-II reverse transcription system 
(Promega, WI, USA). The reactions were carried out according to the following 
protocol: 1µg total RNA, 1µl Oligo dT was topped up with DEPC-treated water to 
10µl and pre-heated at 70ºC for 5 minutes, followed by cooling on ice. Reaction 
mixture consisting of 4µl of ImProm-II 5× reaction buffer, 2.4µl MgCl2 (25mM), 
1.1µl DEPC-treated water, 1µl of dNTP (10mM), 1µl ImProm-II reverse transcriptase 
and 0.5µl RNAsin Ribonuclease inhibitor was then added to each sample before run 
was resumed at 25ºC for 5 minutes, 42ºC for one hour and ended with 70ºC for 15 
minutes. 
 
4.7 Conventional Polymerase Chain Reaction (PCR) 
PCR was performed using the HotStarTag (QIAGEN, Hilden, Germany) kit to 
amplify DLEC1 and GAPDH by using primers as listed in Table 4.7.1. PCR reaction 
conditions were optimized to the following composition: 100ng of cDNA template, 
1.25 µl of 10× reaction buffer, 0.6µM of each primer, 0.2mM dNTP, 0.1µl 
HotStarTag enzyme. The PCR reactions have been set up according to the conditions 
in Table 4.7.2. PCR products were then separated by agarose gell electrophoresis and 
analyzed using Gel Logic 200 Imaging System and the Molecular Imaging Software 
(Version 4.0, Eastman Kodak Company, USA).  
Gene Primer 
Name 
Sequence Cycles Annealing 
Temperature 
(ºC) 




DLEC1 DLEC1 A TTCCTCCCTCGCCTACTC 38 58 
 DLEC1 B AAACTCATCCAGCCGCTG  56 
GAPDH GAPDH 33 GATGACCTTGCCCAGCCT 17 58 
 GAPDH 55 ATCTCTGCCCCCTCTGCTGA  64 
Table 4.7.1 List of primers used for PCR reactions.  
 
Step Temperature (ºC) Duration 
Denaturation 95 10min 
Annealing 94 30s 
 Annealing temperature for 
primers   
30s 
 72 30s 
Final elongation 72 7min 
Table 4.7.2 Thermo-cycling conditions for PCR. If the forward and reverse primers 
differ in their annealing temperatures, the lower temperature was used. 
 
4.8 Real-time Quantitative PCR 
Primers for real-time PCR were designed using the LightCycler Probe Design 
Software, version 1.0 (Roche, Meylan, France). Table 4.8.1 shows the primers used 
for the amplification of DLEC1 and GAPDH. Real-time PCR was performed on the 
LightCycler (Roche) using the LightCycler-RNA Amplification Kit SYBR Green I 
(Roche). The specificity of the amplification was assessed by electrophoretic 
separation of the amplified products and melting curve analysis. Relative DLEC1 
expression was quantified after normalization with GAPDH. 
 







Sequence Cycles Annealing 
Temperature 
(ºC) 
DLEC1 DLEC1 A CACGGAAGAGGCATCG 38 58 
 DLEC1 B ATAAGCCGGAAGTAGTGT  56 
GAPDH GAPDH 33 AGCAATGCCTCCTGCACCAC
CAAC 
17 58 
 GAPDH 55 CCGGAGGGGCCATCCACAGT
CT 
 64 
Table 4.8.1 List of primers used for Real-time PCR reactions. 
 
4.9 Cell proliferation assays 
Cells were seeded in a volume of 100 µl at a density of 1000 cells/well in 96-
well plates and allowed to attach overnight. The medium was then replaced with 
media containing the various treatments described in RESULTS. Cells were 
maintained in treatment medium for 6 days and cell growth was monitored using 
WST1 assay (Roche) at various time points. On the day of the assay, 10 µl of WST1 
was added to each well, and the cells were incubated for a further 3 hr at 37ºC, 5% 
CO2, in a humidified incubator. Absorbance readings of each well at 405nm were 
taken using an uQuant spectrometer (Bio-Tek Instrument Incorporated, Vermont, 
USA). Data are expressed as percentages of absorbance readings from control wells. 
 
4.10 Colony formation assay 




Cells were plated at density of 0.3×106 per well (6-well plate) and treated with 
u0126. 48 hrs post treatment, the cells were trypsinized and plated in a 6-well plate, 
and allowed to grow for two weeks. Surviving colonies were counted after staining 
with crystal violet.  
 
4.11 Flow cytomery   
Cells were seeded in a volume of 2 ml at a density of 0.3 million cells/well in 6-
well plates and allowed to attach overnight. The medium was then replaced with 
media containing the various treatments described in RESULTS. After the treatments, 
the cells were harvested by trypsinization, washed twice with PBS, and fixed 
overnight with 70% ethanol. The fixed cells were washed with PBS and incubated in 
the staining solution (PBS containing RNase, triton, propidium iodide) for 15 min at 
37 ºC. The stained cells were then filtered and subjected to FACScan flow cytometer. 
10000 events were collected per sample. Data acquisition and cell cycle analysis were 
performed using WinMDI (Version 2.8) software.  
 
4.12 Protein Extraction and Quantification 
Total protein was extracted using cell lysis buffer (Cell Signaling Technology) 
containing 1% Triton and 1mM PMSF and lysed by sonication (Sonics VC-130, 
Analis Belgium). The supernatant containing total cell lysate was retained. Protein 
concentrations were quantified by Bradford Method (Bio-Rad Laboratories, CA, 
USA) and read using a uQuant spectrometer (Bio-Tek Instrument Incorporated, 
Vermont, USA). 




4.13 Immunoblotting  Analysis 
30 μg of total protein was subjected to SDS-PAGE on a 4% stacking gel and 
7.5% resolving gel for the analysis of DLEC1, phosphorylated ERK and GAPDH 
expressions. Proteins were transferred to a nitrocellulose membrane (Hybond C-Extra, 
Amersham Biosciences, UK) and blocked for 1 hour in PBS solution containing 0.1% 
Tween 20 and 5% (w/v) non-fat milk powder. The membrane was then incubated with 
primary antibodies (anti-DLEC1 (Sigma-Aldrich, MO), anti-p-ERK (Cell Signaling 
Technology, MA) and anti-GAPDH (Chemicon International, Inc, Ternecula, CA) for 
1 hour (overnight for DLEC1 antibody) and subsequently with an anti-rabbit or an 
anti-mouse secondary antibody for 1 hour. SuperSignal® West Dura (Pierce 
Biotechnology, Inc, Rockford, IL) chemiluminescent substrate was used to detect the 
bound antibodies. The membrane was then exposed to Kodak BioMax film (Eastman 
Kodak, Rochester, NY). 
 
4.14 RNA samples from patients  
Twenty anonymized human colorectal carcinoma and matched adjacent non-
malignant colon tissues were obtained from the NUH-NUS Tissue Repository, 
Singapore. All  samples were harvested after obtaining written informed consent from 
patients. This study was approved by the Institutional Review Board, National 
University of Singapore, Singapore 
 
4.15 Statistical analysis 
In the Real-time Quantitative RT-PCR, cell proliferation and flow cytometry 
assays, the statistical significance of the differences between the control and treatment 




groups were assessed by unpaired t-test. A two-tailed P-value of less than 0.05 was 
considered as statistically significant. All of the data were analyzed using GraphPad 




























5 RESULTS  
5.1 Function of DLEC1  
5.1.1 DLEC1 was down-regulated in patient tumor samples 
The level of mRNA expression of DLEC1 was examined in ten pairs of human 
colorectal tumor samples, each matched with corresponding adjacent normal tissue. 
The results showed that in six pairs of samples, DLEC1 has been down-regulated (92, 
97, 3, 11, 44 and 59) in the tumor samples, as compared to their adjacent normal 
tissues (Figure 5.1.1).  
This result suggested that DLEC1 is a likely tumor suppressor gene in human 
colorectal tumors. Other studies have shown similar results in hepatocellular 
carcinoma (HCC), where DLEC1 expression was robust in normal liver tissues but 
suppressed in majority of HCC cell lines and liver tumor samples examined (Qiu et 
al., 2008). 
Figure 5.1.1 Expression level of DLEC1 in patient samples. The total RNA samples from 
ten different patients have been collected and screened for DLEC1 expression level by 
RT-PCR. The expression levels in tumor samples (T) were compared to their adjacent 
normal tissue (N). β-actin has been used as the loading control.  
 





Previous studies on DLEC1 showed that it was a candidate tumor suppressor 
gene. The over-expression of DLEC1 in hepatocellular carcinoma (HCC) cell lines 
such as HepG2 and SK-Hep-1 resulted in the inhibition of cell proliferation, reduction 
in cell size and G1 cell cycle arrest (Qiu et al., 2008).  In this study, we further 
validated the tumor suppressing properties of DLEC1 in the HCT116 cell line.  
The cells were subjected to DLEC1 transient over-expression, with 10µM 
zeocin as the selecting reagent. 48 hrs after the transfection, the cells have been 
harvested and re-plated in 96-well plates. Cell survival assays have been carried out 
for six consecutive days. The results in Figure 5.1.2 showed that DLEC1 over-
expression significantly inhibited the cell proliferation, as compared to the pcDNA3.1 
vector control. This suggested that DLEC1 over-expression affected cell viability and 
proliferation.  





















Figure 5.1.2 Inhibition of cell growth by DLEC1 in vitro. WST1, a colorimetric cell 
proliferation reagent was used to determine cell growth relative to the pcDNA3.1 vector 
control. Representative results of cell proliferation were shown. The absorbance value 
reflected the number of viable cells. Mean values of triplicate samples were plotted, with 
error bar indicating the standard deviation. Experimental differences were tested for 






5.1.3 Reduced colony formation by DLEC1 over-expression in HCT116 cell line 
DLEC1 over-expression suppressed colony formation in HCT116 cell line, as 
shown in Figure 5.1.3. Cells which were transfected with pcDNA3.1-DLEC1 plasmid 
have less number of colonies as compared to the pcDNA3.1 vector control. The size 
of the colonies was also markedly smaller in DLEC1 over-expressed cells. This 
suggested that DLEC1 over-expression affects cell viability and proliferation status of 
HCT116 cells.  
 
Figure 5.1.3 Inhibition of colony formation by DLEC1. Colony formation assay using 
DLEC1 over-expressed HCT116 cells. Results showed reduced number and size of 
colonies in DLEC1 over-expressed cells as compared to cells transfected with pcDNA3.1 






5.1.4 DLEC1 over-expression induced G1 arrest in HCT116 cell line  
 
 
Figure 5.1.4 DLEC1 over-expression induced cell cycle arrest or apoptosis in HCT116 
cells. Stable clones over-expressed with DLEC1 were established and cell cycle analysis 
has been carried out. Results showed DLEC1 over-expression caused G1 cell cycle arrest 
pcDNA3.1-3 pcDNA3.1-4 DLEC1-3 
DLEC1-7 DLEC1-15 DLEC1-11 





in 6 out of the 7 stable clones established, while it caused apoptosis in 1 clone, as 
compared to the two pcDNA3.1 control clones. Statistical values were shown in Table 
5.2.3. 
Since we have shown previously that DLEC1 over-expression could suppress 
cell growth, we would like to investigate the possible mechanism of this suppression 
by analyzing the cell cycle progression of HCT116 cells over-expressed with DLEC1. 
Seven stable clones with DLEC1 over-expression and two stable clones transfected 
with pcDNA3.1 vector control have been established, and cell cycle distribution have 
been analyzed by using propidium iodide incorporation method. Results in Figure 
5.1.4 and Table 5.1.1 showed that DLEC1 over-expression has caused G1 cell cycle 
arrest in six out of the seven stable clones, and apoptosis in one out of the seven stable 
clones, as compared to the pcDNA3.1 vector control. This suggested that the effect of 
DLEC1 on cell growth was mainly a result of G1 cycle arrest, and partially apoptosis.  
 
Table 5.1.1 Statistical values of the cell cycle analysis of DLEC1 over-expression. Values 
highlighted in bold indicated significant change as compared to the two pcDNA3.1 
control clones.  
 Sub-G1 (%) G1 (%) S (%) G2/M (%) 
pcDNA3.1-3 11.58 41.06 25.98 20.99 
pcDNA3.1-4 16.38 47.88 19.94 16.69 
DLEC1-3 7.07 57.60 25.25 14.95 
DLEC1-4 10.14 55.67 18.69 18.12 
DLEC1-5 8.64 53.40 26.05 16.61 
DLEC1-6 14.85 66.38 12.00 8.01 
DLEC1-7 6.86 57.31 18.46 17.85 
DLEC1-11 12.97 54.81 16.76 16.41 





5.1.5 Transient knockdown of DLEC1 in HCT116 cell line 
Since we have demonstrated that DLEC1 over-expression inhibited cell 
proliferation and induced G1 cell-cycle arrest, we would like to investigate if 
knocking down DLEC1 could reverse some of its effect.  Transient knockdown was 
performed by transfecting HCT116 cells with DLEC1 SiRNA and universal scramble 
control for 72 hours. After the transfection, the cells have been harvested and total 
RNA has been extracted. The results in Figure 5.1.5 have shown that DLEC1 
knockdown was successful using SiRNA4. Hence this SiRNA has been selected for 
further DLEC1 knockdown experiments.  
 
Figure 5.1.5 Transient DLEC1 knockdown in HCT116. Cells were transfected with 
DLEC1 SiRNA (4, 5, 6) and universal scramble control. 72 hours after the transfection, 
the cells have been harvested and total has been extracted, and subjected to RT-PCR 
analysis. GAPDH has been used as the loading control. Results have shown that DLEC1 
SiRNA 4 was most effective for DLEC1 knockdown, hence this SiRNA sequence has 
been selected to be used for further experiments.   
 
5.1.6 Knocking down of DLEC1 caused significant increase in apoptotic cells 
In the previous section we have identified the siRNA sequence that is most 
effective in knocking down DLEC1 in HCT116 cell line. We then knocked down 
DLEC1 in the HCT116 cell line using this siRNA. 72 hours after the transfection, the 





Figure 5.1.6 and Table 5.1.2 showed that DLEC1 knockdown significantly reduced 
the number of cells in G1 phase, and an increase in sub-G1 phase has also been 
observed.  
Figure 5.1.6 Cell cycle phase distribution of HCT116 cells after DLEC1 transient 
knockdown. Statistical values are shown in Table 5.2.8. 
 
 Sub-G1 (%) G1 (%) S (%) G2/M (%) 
Scramble 
control 
5.29 82.23 3.69 8.93 
DLEC1 
siRNA 
53.65 38.37 4.04 4.25 




5.1.7 Localization of DLEC1 
To better understand the function of DLEC1 and the possible mechanism 
involved, we were interested to find out the localization of DLEC1. HCT116 cells 
have been transiently over-expressed with DLEC1 plasmid. 48 hours after the 






to separate the nucleus proteins from the cytoplasmic proteins. The fractionated 
proteins were then analyzed using immunoblotting. The results in Figure 5.1.7 
showed that DLEC1 was primarily located in the cytoplasm.   
 
 
Figure 5.1.7 Localization of DLEC1. HCT116 cells have been transiently transfected 
with pcDNA3.1 vector control and pcDNA3.1-DLEC1 expression plasmid. 48 hours 
after transfection, the cells have been harvested, cell fractionation has been carried out 
to obtain the nucleus and the cytoplasmic proteins. The fractionated proteins were then 
subjected to immunoblotting analysis using DLEC1 anbibody. Lamin-B has been used 
as the nucleus marker, and GAPDH has been used as the cytoplasmic marker. The 
results showed that DLEC1 was primarily located in the nucleus. 
 
5.1.8 Re-localization of DLEC1 into the nucleus by Gal4 tag and the effect of 
re-localization on colony formation 
In the previous experiment we have shown that DLEC1 was mainly located in 
the cytoplasm. To get some primary information about the possible mechanism of 
function of DLEC1, we would like to know whether the tumor suppressing function is 
dependent on the localization of DLEC1. We constructed a Gal4 tagged DLEC1, 
since Gal4 was known to have strong nucleus localizing sequence that will cause the 





shown in Figure 5.1.8, the re-localization of DLEC1 into the nucleus was successful, 
as indicated by the immunofluorescent results. 
 
Figure 5.1.8 Immunoflurescent result showing the re-localization of DLEC1 into the 
nucleus by Gal4-tagged DLEC1. Cells were transfected with Gal4-DLEC1 expression 
plasmid, and co-stained with the nucleus indicator DAPI (4’,6-diamidino-2-
phenylindole,blue) and anti-Gal4 antibody (green).  
 
After confirming the re-localization of DLEC1 into the nucleus by Gal4- tag, we 
then carried on to investigate if the re-localization will cause any change on the 
inhibitory effect of DLEC1. We did the preliminary test on colony formation, and we 
have observed significant difference between cells transfected with Gal4 vector 





number and size of the colonies formed.  This result demonstrated that DLEC1 could 
still exert its growth inhibitory effect after being translocated in the nucleus, which 
implied that the localization of DLEC1 is not affecting its function as a tumor 
suppressor gene. 
Figure 5.1.9 Effect of DLEC1 re-localization on colony formation. Colony formation 
assay using HCT116 cells over-expressed with Gal4 vector control or Gal4-DLEC1 
plasmid. Results showed reduced number and size of colonies in Gal4-DLEC1 
transfected cells as compared to cells transfected with Gal4 vector control. 
 
5.1.9 The level of transcription factor AP2α2 increased with DLEC1 expression 
level 
To study the possible mechanism of how DLEC1 inhibited the growth of cancer 
cells, we screened for a number of elements that may be the downstream mediators of 
DLEC1, including cyclin D1, p21, SP1, AP2, etc. We found that in DLEC1 stable 





(Figure 5.1.10). This suggested that the growth inhibitory effect of DLEC1 may be 





Figure 5.1.10 up-regulation of AP2α2 in stable clones expressing DLEC1.  GAPDH has 
been used as a loading control.  
 
5.2 Regulation of DLEC1  
5.2.1 Emodin up-regulated the expression of DLEC1 in a dose-dependent 
manner in HCT116 cell line 
In order to identify the possible mechanism that regulates DLEC1 expression, 
we exposed the cells to different types of stresses (drug treatments, serum starvation, 
UV radiation, cold shock, etc) and monitored their effect on the mRNA level of 
DLEC1 in HCT116 cell line.  We observed that exposing the cells to Emodin, an 
active constituent of Rheum palmatum, significantly up-regulated the mRNA level of 
DLEC1 (data not shown). To verify this result, we treated HCT116 cells with 
different concentrations of Emodin to study their effect on DLEC1 expression. The 
results from conventional RT-PCR and quantitative real time PCR both showed that 
 pcDNA3.1                               DLEC1                            a 







treating with Emodin up-regulated the mRNA level of DLEC1 in HCT116 cell line, in 





























Figure 5.2.1 Induction of DLEC1 by Emodin in HCT116 cells. Cells were treated with 
different concentrations of Emodin (0, 2, 10, 50, 100µM) for 48 hrs. Dimethyl sulfoxide 
(DMSO) was used as a control. GAPDH has been used as an internal loading control. 
Emodin treatment induced the expression of DLEC1 mRNA (~300bp) in a dose 
dependent manner. (a) A representative RT-PCR result. (b) Real time PCR result, 








5.2.2 ERK and PI3K inhibitor stimulated DLEC1 expression 
The drug Emodin is a board spectrum inhibitor that can target many key 
elements in several molecular pathways (Srinivas et al., 2007). Previous studies in our 
lab have also shown that DLEC1 is down-regulated in HCC (Qiu et al., 2008), in 
which the PI3K-AKT-mTOR, JNK-SAPK and Ras-Raf-MEK-ERK signaling 
pathways are frequently activated (Boyault et al., 2007; Calvisi et al., 2006; Hopfner 
et al., 2008; Schmidt et al., 1997). Therefore, in order to identify the specific pathway 
that is responsible for the up-regulation of DLEC1 by Emodin, we screened the effect 
of the specific inhibitors of several key elements: LY294002 (PI3K inhibitor), 
SP600125 (JNK inhibitor), SB239063 (p38 MAPK inhibitor) and u0126 (ERK 
inhibitor). The level of DLEC1 mRNA expression after the treatment was detected by 













































Figure 5.2.2 Induction of DLEC1 by different drug treatments in HCT116 cells. Cells 
were treated with different drugs at their commonly used doses for 48 hrs. Dimethyl 
sulfoxide (DMSO) was used as a control. GAPDH has been used as an internal loading 
control. Treatment with LY294002 and u0126 induced the expression of DLEC1 mRNA 
(~300bp). (a) A representative RT-PCR result. (b) Real time PCR result, standardized to 
GAPDH  mRNA, the bar indicate the standard deviation. 
 
The results from the PCR analysis showed that DLEC1 expression was up-
regulated by PI3K inhibitor and ERK inhibitor, but not JNK inhibitor and p38 MAPK 
inhibitor. This suggested that the molecular pathway that regulated DLEC1 
expression may involve the elements PI3K and ERK, but not JNK and p38 MAPK. 
From the results, we further noticed that the effect of u0126 on DLEC1 expression 
was more significant as compared to LY294002, therefore we carried out our 
subsequent studies focusing on the pathway involving ERK. 
 






The results in part 5.2.2 showed that u0126 might be a potential drug that 
induces DLEC1 expression in HCT116 cell line. To investigate whether the induction 
is correlated with the suppressed phosphorylation of ERK, immunoblotting analysis 
was carried out to validate the potency of u0126 as a MEK inhibitor in HCT116 cells. 
The cells were treated with different concentrations of u0126 (2, 5, 10, 25, 50µM). 48 
hrs after the treatment, cells were harvest and total protein was extracted. The levels 
of phosphorylated ERK 1/2 were used as an indicator to verify MEK inhibition. 
Results showed that u0126 inhibited the phosphorylation of ERK in a dose dependent 
manner.  
 
Figure 5.2.3  Inhibition of ERK phosphorylation by u0126 in HCT116 cell line. Cells 
were treated with different concentrations of u0126 (2, 5, 10, 25, 50µM). Cells were 
harvested for protein extraction 48 hrs after treatment and Western blot analysis was 
performed, using an antibody specific for phosphorylated ERK1 (44kD) and ERK2 
(42kD). Phosphorylation of ERK1/2 decreased as the concentration of u0126 increased. 
Total ERK was used as an internal loading control.  
 
5.2.4 U0126 up-regulated the expression of DLEC1 in a dose-dependent 
manner in HCT116 cell line  
To test the effect of u0126 on DLEC1 expression level, we treated HCT116 
cells with different concentrations of u0126 (2, 5, 10, 25 and 50µM). 48 hours after 





PCR and immunoblotting were carried out to analyze the level of DLEC1. The results 
showed that u0126 up-regulated the expression of DLEC1 in a dose-dependent 
manner, both at the mRNA level and the protein level.  
 
 
Figure 5.2.4  Induction of DLEC1 expression by u0126 in HCT116 cell line. Cells were 
treated with different concentrations of u0126 (2, 5, 10, 25, 50µM). DMSO was used as 
the control. GAPDH was used as the internal loading control. U0126 induced the 
expression of DLEC1 in a dose-dependent manner, both at the mRNA level and the 
protein level. (a) a representative RT-PCR result; (b) a representative Western blot 
result.  
 
5.2.5 U0126 inhibited cell growth in HCT 116 cell line  
We had shown earlier that DLEC1 over-expression inhibited cell growth, 







We have also demonstrated that treating HCT116 cells with u0126 up-regulated the 
levels of DLEC1 in a dose dependent manner. Therefore we would like to examine if 
treating HCT116 cells with u0126 will have any similar effect on cell growth and cell 
cycle progression brought about by DLEC1 over-expression, and whether the effects 
were caused by DLEC1 up-regulation.  
We first examined the effect of u0126 on cell growth of HCT116 cells by using 
WST-1 cell proliferation assay. The results were shown in Figure 5.2.5. 
 
Figure 5.2.5 Inhibition of cell proliferation by u0126. HCT116 cells were treated for with 
different concentrations of u0126. WST-1, a colorimetric proliferation assay reagent was 
used to determine cell growth. The absorbance value reflected the number of viable 
cells. Mean values of triplicate samples were plotted, with error bar indicating the 
standard deviation. 
 
The results from these cell proliferation assays indicated that in HCT116 cell 
lines, treating with u0126 inhibited cell growth as compared to the DMSO control. 






5.2.6 U0126 inhibited colony formation in HCT116 cell line 
 
 
Figure 5.2.6 Inhibition of colony formation by u0126. Results showed reduced number 
of colonies as the concentration of u0126 increased.  Results shown are representative of 






Treating HCT116 cells with u0126 reduced the colony formation in a dose 
dependent manner, as shown in Figure 5.2.6. The number of colonies and the total 
area occupied by colonies decreased with increasing dose of u0126, where nearly no 
colony was formed when treated with 50µM of u0126. However, at lower dose (2µM 
and 10µM), the size of the colonies formed was not significantly smaller than the 
DMSO control.  
 
5.2.7 U0126 caused increase in sub-G1 phase in HCT116  
We have shown previously that u0126 treatment suppressed the growth of 
HCT116 in a dose dependent manner, both in terms of cell proliferation and colony 
formation. In order to study if these changes in cell growth were associated with 
change in cell cycle progression, flow cytometry analysis was carried out.  
In HCT116 wild type cells, treating with u0126 did not cause significant G1 
phase arrest that has been observed in DLEC1 over-expressing cells. Instead, a slight 
increase in Sub-G1 apoptotic cells have been observed, which showed a dose-













Figure 5.2.7 u0126 treatment caused slight increase in Sub-G1 phase in wild type 
HCT116 cells. Statistical values were shown in Table 5.2.1  
 
 Sub-G1 (%) G1 (%) S (%) G2/M (%) 
Ctrl 1.81 74.02 8.2 16.98
2µM 2.17 72.72 9.94 16.67
5µM 3.33 74.64 8.82 14.81
10µM 3.42 76 7.89 13.81
25µM 3.8 76.08 6.6 14.49





Table 5.2.1 Statistical values of the cell cycle analysis of u0126 treatment on wild type 
HCT116 cells. Values highlighted in bold indicated significant change as compared to 
the DMSO control.  
 
Surprisingly, in HCT116 cells with p53 knock out, we observed a more 
significant Sub-G1 apoptotic portion, and a slight increase in G1 phase arrest, as the 
concentration of u0126 increased (Figure 5.2.8 and Table 5.2.2). This led us to 









Figure 5.2.8 u0126 treatment caused more significant increase in Sub-G1 phase in 
HCT116 p53KO cells. Statistical values were shown in Table 5.2.2  
 
 Sub-G1 (%) G1 (%) S (%) G2/M (%) 
Ctrl 1.73 58.78 13.31 27.69
2µM 2.04 54.84 13.09 31.18
5µM 3.43 55.39 13.11 29.46
10µM 4.19 59.66 15.47 23.9
25µM 9.72 60.99 16.09 16.96
50µM 12.75 64.91 14.35 11.81
Table 5.2.2 Statistical values of the cell cycle analysis of u0126 treatment on HCT116 
p53KO cells. Values highlighted in bold indicated significant change as compared to the 
DMSO control. 
 
5.2.8 Knocking down of DLEC1 changed the effect of u0126 on HCT116 cell 
line 
Since we postulate that DLEC1 might be one of the players that mediated the 
growth inhibitory effect of u0126, transient knockdown was performed to investigate 
if there were any significant changes in cell growth and cell cycle arrest in the 





DLEC1 SiRNA for 24 hrs, after which u0126 treatment was carried out using 
different concentrations of drug. 48 hrs after the drug treatment, the cells were 
harvested and flow cytometry analysis was carried out. The result in Figure 5.2.8 and 
Table 5.2.2 showed that DLEC1 knockdown varied the effect of u0126 on HCT116 
cell cycle progression. In cells with DLEC1 transient knockdown, cells displayed G1 
phase arrest only with high doses of u0126 (25µM and 50µM). While in cells 
transfected with the scramble control, low doses of u0126 induced apoptosis, and high 
doses caused G2/M phase arrest.  
With this, we were confident that any changes in cell cycle distribution upon 
u0126 treatment in DLEC1 knockdown cells could be attributed to DLEC1. Similar 
effect has also been observed in other cell lines (experiments conducted by other 












Figure 5.2.9 Cell cycle phase distribution of HCT116 cells treated with u0126 after 








 Sub-G1 (%) G1 (%) S (%) G2/M (%) 
 SCR SiRNA SCR SiRNA SCR SiRNA SCR SiRNA
Ctrl 5.29 53.65 82.23 38.37 3.69 4.04 8.93 4.25
2µM 9.68 56.62 73.65 33.6 5.94 4.48 11.09 5.47
5µM 13.5 54.94 68.27 36.11 7.54 4.37 10.89 4.73
10µM 11.31 60.75 75.62 32.72 5 3.6 8.22 3.26
25µM 8.64 45.29 69.66 46 4.83 4.74 16.91 4.28
50µM 8.45 31.05 69.3 55.86 4.18 6.43 18.24 7.1
Table 5.2.3 Statistical values of the cell cycle analysis of u0126 treatment on HCT116 
cells with transient DLEC1 knockdown. Values highlighted in bold indicated significant 





















6.1 The tumor suppressing effect of DLEC1 in HCT116 cell line 
Frequent deletion of chromosome 3p has been reported as one of the earliest 
molecular changes in tumors of the lung, nasopharynx, breast and gastrointestinal 
tract, etc (Hesson et al., 2007; Hung et al., 1995; Kok et al., 1997; Wistuba et al., 
2000).  DLEC1 is located at the locus 3p21.3. It has been shown that DLEC1 is a 
candidate tumor suppressor gene in various cancers, including ovarian cancer (Kwong 
et al., 2006), esophageal carcinoma (Daigo et al., 1999), hepatocellular carcinoma 
(Qiu et al., 2008) and lung cancers (Rauch et al., 2006). In this study, we studied the 
effects of DLEC1 in HCT116 cell line to provide the preliminary evidence that 
DLEC1 was a candidate tumor suppressor in colorectal cancer.  
 
6.1.1 Down-regulation of DLEC1 in patient tumor samples 
Our study showed that DLEC1 was down-regulated in tumor samples as 
compared to their adjacent normal tissues. Other studies have demonstrated that 
DLEC1 expression was robust in normal tissues but suppressed in the majority of 
tumor samples and cell lines (Qiu et al., 2008; Ying et al., 2008). This served as the 
preliminary evidence that DLEC1 was a candidate tumor suppressor gene in 
colorectal carcinoma.  
A number of studies have shown that the mechanism of DLEC1 down-
regulation is promoter hypermethylation, and the methylation status was directly 
correlated to the AJCC staging of the tumors (Qiu et al., 2008). This further supported 





down-regulation of DLEC1 by promoter methylation was associated with staging of 
tumors, it could be used as a biomarker in the future. 
 
6.1.2 Inhibition of cell proliferation and colony formation by DLEC1 over-
expression 
To further support the hypothesis that DLEC1 is a candidate tumor suppressor 
gene in colorectal cancer, we carried out cell proliferation and anchorage dependent 
colony formation studies in HCT116 cell line by over-expressing DLEC1. We have 
observed that transient over-expression of DLEC1 markedly inhibited both cell 
proliferation and colony formation as compared to the empty vector control. Similar 
tumor suppressive properties have been observed in other cancer cell lines including 
HCC cell lines HepG2 and Hep3B (data not shown). It has also been shown that the 
proliferation and invasiveness of DLEC1 expressing cells are greatly reduced with a 
dramatic reduction in tumorigenic potential in in vivo animal models (Kwong et al., 
2007). These findings suggested that DLEC1 is a functional tumor suppressor gene 
involved in multiple tumorigensis.  
 
6.1.3 Cell cycle arrest by DLEC1 over-expression 
After observing the inhibiting effect of DLEC1 on cell proliferation and colony 
formation in HCT116 cell line, we further investigated the possible effect of DLEC1 
on cell cycle progression in order to gain further insight to the mechanism of its 
inhibitory effect on growth of cancer cells. However, no significant change in cell 
cycle distribution was observed with transient DLEC1 over-expression in HCT116 





expressing DLEC1, and observed that DLEC1 caused G1 cell cycle arrest in six out of 
seven stable clones, and apoptosis in the remaining clone. This suggested that the 
tumor suppressing ability of DLEC1 may be largely due to its role in G1 arrest, 
possibly combined with some effect on apoptosis. The underlying mechanism of this 
arrest needs to be investigated further. Although it is possible that DLEC1 is causing 
the G1 arrest directly, but a more likely mechanism will be through acting on other 
possible mediators of G1 arrest including cyclin D1, p21, p27 and p53, etc. 
 
6.1.4 Knocking down of DLEC1 caused significant increase in apoptotic cells 
In the earlier part of the study we have shown that DLEC1 over-expression 
could lead to an increase in G1 cycle arrest. We then hypothesized that knocking 
down DLEC1 could reverse the effect of DLEC1 over-expression. We tested our 
hypothesis by transiently knocking down DLEC1 with siRNA. Surprisingly, although 
knocking down of DLEC1 did reduce the percentage of cells in G1 phase, it also 
caused a significant increase in cell apoptosis. This led us to suspect that although 
DLEC1 possesses tumor suppressing effect in various tumor samples and cell lines, a 
basal level expression may be essential for the survival of the cells. Since this was the 
first time this effect of DLEC1 has been observed, we would like to further confirm it 
by conducting similar experiments in other cell lines in the future.    
 
6.1.5 Localization of DLEC1 
Investigating the cellular localization of DLEC1 could provide us with clues 
about the mechanism of its function. Our immunoblotting result showed that it is only 





A study conducted by our lab member reported that a bipartite nuclear 
localization signal was identified in the DLEC1 protein (data not shown). Combining 
with the results in our study, we could hypothesize that a transient importation of 
DLEC1 into the nucleus may be required for DLEC1 to exert its effect on cell cycle 
progression. To conduct a preliminary test on this hypothesis, we investigated the 
effect of re-localizing DLEC1 into the nucleus on colony formation. We achieved the 
localization by creating a Gal4- tagged DLEC1 plasmid and transfecting it into 
HCT116 cells, which was confirmed by immunofluorescent staining. The result of 
this experiment showed no significant difference exists between cells transfected with 
pcDNA3.1-DLEC1 and those transfected with Gal4-DLEC1 plasmid in terms of 
colony formation. This implied that the cellular localization of DLEC1 was not 
crucial for its tumor suppressing effect, probably because it will be transiently 
imported into the nucleus at some point in time to exert its function. This could serve 
as the preliminary evidence to support our hypothesis, which is going to be studied in 
depth in the future. 
 
6.1.6 DLEC1 induced expression of AP2α2 
In the HCT116 stable clones expressing DLEC1, we screened for the mRNA 
level of a number of elements that may be the mediator of DLEC1 induced cell 
growth inhibition. These include the cyclins (A2, B1, E1, D1, D3), p21, the 
transcription factors from AP2 family and SP family. Out of all these elements, we 
found that AP2α2 has been up-regulated in DLEC1 stable clones as compared to the 
pcDNA3.1 control. This suggested that AP2α2 may play an important role in the 





AP2 (activator protein 2) are transcription factors involved in the regulation of 
cell proliferation, differentiation, apoptosis and carcinogenesis (Pellikainen and 
Kosma, 2007). It forms a family of highly homologous proteins AP-2α, AP-2β and 
AP-2γ (Williams et al., 1988; Cheng et al., 2002; Moser et al., 1995). Over-
expression of AP-2α, in particular, is associated with inhibition of cell growth and 
induction of cell cycle arrest/apoptosis in various human cancer cell lines (Wajapeyee 
et al., 2003). Study by Li et al. (2009) recently demonstrated that AP-2α suppresses 
intestinal tumorigenesis in vivo in the Apcmin mouse.  
 
6.2 Regulation of DLEC1 expression 
It has been reported in previous studies that DLEC1 was down-regulated in 
various cancers, including nasopharengeal carcinoma (Chou et al., 2008; Kwong et 
al., 2007), cervical carcinoma (Kwong et al., 2006; Zhang et al., 2008), non-small cell 
lung carcinoma (Seng et al., 2008; Rauch et al., 2006), colon and gastric carcinoma 
(Roberts and Der, 2007; Ying et al., 2009). This led us to speculate whether the 
down-regulation of DLEC1 was associated with the constitutive activation of growth 
signaling pathways often detected in cancers. These include the PI3K-Akt-mTOR, 
JNK-SAPK and Ras-Raf-MEK-ERK pathways.  In this study, we mainly investigated 
the regulation of DLEC1 in HCT116, a human colorectal tumor cell line, where at 
least one of these signaling pathways was constitutively activated.   
 
6.2.1 Induction of DLEC1 expression by LY29 and u0126 
The study of DLEC1 regulation started by subjecting HCT116 cells to an initial 





LY29 and u0126 emerged as potential regulators of DLEC1 in HCT116 cell line. This 
led us to the hypothesis that PI3K pathway and ERK pathway may be involved in the 
regulation of DLEC1 expression. We further selected u0126 as our target of study 
because its stimulating effect on DLEC1 was more significant as compared to LY29.  
In this study, we found that u0126 up-regulated DLEC1 in HCT 116 cell line, in 
both mRNA and protein level, and in a dose-dependent manner, as compared to the 
DMSO solvent control. It has been shown by other members of the lab, that u0126 
has a similar effect on DLEC1 in HCC cell lines HepG2 and Hep3B (data not shown), 
which eliminated the possibility of cell specific response.  
 
6.2.2 Mechanism of DLEC1 up-regulation by u0126 
u0126 has been reported to be a potent MEK inhibitor that is highly selective 
(Duncia et al., 1998). In this study, we have validated the potency of u0126 as a MEK 
inhibitor in HCT116 cell line by using Western Blot (Figure 5.1.3). Levels of 
phosphorylated ERK1/2 were used as an indicator of MEK inhibition as these two 
isoforms of ERK are the direct downstream effectors of MEK (Wiesenauer et al., 
2004) and can be phosphorylated by MEK on both tyrosine and threonine residues 
(Davies et al., 2000). In other studies carried out in the lab, it has been demonstrated 
that treating HCC cell lines with u0124, an inactive analogue of u0126, failed to up-
regulated DLEC1 expression level (data not shown).  
The exact mechanism underlying the up-regulation of DLEC1 by u0126 
remains unclear. However, it has been reported in previous studies that DLEC1 was 
silenced by promoter CpG mehylation in colon and gastric cancers (Ying et al., 2008) 





also shown that inhibition of ERK down-regulated the expression of DNMT1, which 
was responsible for the de novo DNA methylation (Lu et al., 2007). Therefore, we 
have reason to hypothesize that the up-regulation of DLEC1 by de-activation of ERK 
is through the down-regulation of DNMT1. Whether DNMT1 activity is also up-
regulated in HCT116 needs to be investigated, because this might help to explain for 
the hypermethylation status of DLEC1 promoter.    
 
6.3 The effect of u0126 on HCT116 cell line 
6.3.1 Rational for studying the effect of u0126 on HCT116 cell line 
u0126 is a potent and highly selective inhibitor of MEK, which is a critical 
member of the Ras-Raf-MEK-ERK pathway. This pathway mediates cellular 
responses to different growth signals and is frequently deregulated in cancer. In recent 
years, MEK has become a new therapeutic target for cancer treatment, and several 
MEK inhibitors were already undergoing clinical trials for cancer treatment. The first 
MEK inhibitor to go into clinical trial, CI-1040, has demonstrated poor clinical 
efficacy. However, the encouraging safety profile of CI-1040 provided the momentum 
to search for more potent analogues (Allen et al., 2003). A number of other MEK 
inhibitors, including AZD6244, RDEA119, are currently under clinical trials in 
advanced cancer patients.  
 It has been shown in the earlier part of this study, that u0126 up-regulated the 
expression of DLEC1 in HCT116 cell line in a dose dependent manner. Although 
u0126 has yet to be a potential cancer therapy, studying the effect of DLEC1 up-





regarding how DLEC1 functions as a tumor suppressor gene in colorectal cancer cell 
lines. 
 
6.3.2 Inhibition of growth and colony formation by u0126 
In tandem with its ability to up-regulate DLEC1 expression, u0126 was found to 
exhibit growth inhibitory effects on HCT116 cell line, especially at higher 
concentrations of 25µM and 50µM where the up-regulation of DLEC1 was most 
significant, as shown by the cell proliferation assay and colony formation assay. This 
suggested that the Ras-Raf-MEK-ERK pathway plays a very important role in the 
growth and survival of HCT116 cells, and DLEC1 may be a downstream effecter of 
this pathway.  
 
6.3.3 Cell cycle arrest by u0126 
U0126 treatment induced an increase in the sub-G1 fraction in the HCT116 cell 
line, suggesting that the growth inhibitory effect of u0126 on HCT116 cell line may 
be caused mainly by apoptosis. We also observed that the effect of u0126 was more 
pronounced in HCT116 cells with p53 being knocked out, which indicated that the 
effect of u0126 maybe p53 dependent. This led us to speculate about the role of p53 
in u0126 caused cell growth inhibition. Whether p53 is playing a role in the regulation 
of DLEC1 expression by the Ras-Raf-MEK-ERK pathway, or p53 is a downstream 







6.3.4 Transient knockdown of DLEC1 in HCT116 cells altered the effect of 
u0126 on cell cycle progression 
We have shown in this study, that u0126 could up-regulate the expression of 
DLEC1 in HCT116 cell line. We have also observed that u0126 could inhibit cell 
growth and induce apoptosis. Hence, transient knockdown of DLEC1 has been carried 
out to investigate if the stimulation of DLEC1 expression was associated with u0126-
induced cell cycle arrest. From our result, we have observed that at low doses of 
u0126 (0 to 10µM), knocking down of DLEC1 protected the cells from apoptosis, as 
compared to the scramble control. While at high doses of u0126 (25 and 50µM), 
where the up-regulation of DLEC1 by u0126 was more significant, cells with DLEC1 
knockdown displayed G1 arrest, as compared to the G2/M arrest in the control cells.  
With this, we were confident that any changes in cell cycle distribution upon 
u0126 treatment in DLEC1 knockdown cells could be attributed to DLEC1. Similar 
effect has also been observed in other cell lines (experiments conducted by other 













In conclusion, through our study, we demonstrated that the inhibition of Ras-
Raf-MEK-ERK pathway could induce the expression of DLEC1 in HCT116 cell line, 
suggesting that DLEC1 may be regulated by this signaling pathway. We also showed 
that DLEC1 exhibited growth inhibitory effects in HCT116 cells, which may be 
caused by a combination of apoptosis and G1 cell cycle arrest. In addition, we 
observed that the transcription factor AP2α2 was up-regulated by DLEC1 over-
expression, which indicated the possible involvement of AP2α2 as a downstream 
















8 FUTURE STUDIES 
We have shown that DLEC1 could be up-regulated by MEK inhibitor u0126 in 
HCT116 cell line. However, the exact mechanism underlying this induction remains 
unclear. We could design experiments to first determine whether the regulation was a 
direct effect through certain ERK response element on the DLEC1 promoter, or 
whether the regulation was indirectly mediated by other elements downstream of 
ERK. 
Further studies should also include investigating the mechanism behind the 
growth arrest in DLEC1 over-expressed cells. The preliminary data in this study 
showed that DLEC1 over-expression could have caused G1 phase arrest and 
apoptosis. Our data also showed that DLEC1 up-regulated the mRNA expression 
level of AP2α2. It is possible that AP2α2 is a candidate element mediating the 
inhibitory effect of DLEC1 on cell growth. Immunoblotting analysis should be carried 
out to verify the up-regulation of AP2α2 (experiment was not conducted in this study 
due to lack of appropriate AP2α2 antibody), as an increase in mRNA level does not 
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